16 completed, 5 unknown, 4 terminated, 2 recruiting. 28 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 28 | Completed 16, Unknown 5, Terminated 4, Recruiting 2, Not yet recruiting 1 |
Follow Levodopa: new trials by email Literature Review of Levodopa trials Research Report on Levodopa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics Levodopa (L-dopa) - Parkinson's Disease | Phase 4 | Not yet recruiting | Beth Israel Deaconess Medical Center | 40 | 2027-07-01 | 2026-08-28 |
| Dopaminergic Therapy for Anhedonia - 2 Carbidopa Levodopa, Placebo - Anhedonia, Depression | Phase 4 | Recruiting | Emory University | 70 | 2023-11-21 | 2026-01-28 |
| Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease levodopa/carbidopa/entacapone - Parkinson Disease | Phase 4 | Unknown | Second Affiliated Hospital of Soochow University | 60 | 2023-11-15 | 2024-02-01 |
| Comparison of Dopamin Level in Idiopathic Parkinson's Patients Levodopa - Parkinson Disease, Treatment Adherence | Phase 4 | Unknown | Ankara Ataturk Sanatorium Training and Research Hospital | 96 | 2023-10-01 | 2023-11-28 |
| Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease Stalevo, Carbidopa and Levodopa Controlled Release Tablets - Parkinson Disease | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 180 | 2022-01-01 | 2023-02-16 |
| eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. Opicapone, L-DOPA/DDCI - Parkinson Disease | Phase 4 | Completed | Bial - Portela C S.A. | 106 | 2021-11-29 | 2025-03-12 |
| Cortical Electrophysiology of Response Inhibition in Parkinson's Disease Levodopa, Clinical DBS Setting, Sham DBS - Parkinson Disease | Phase 4 | Recruiting | Emory University | 80 | 2021-08-09 | 2026-09-03 |
| 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study) Carbidopa/levodopa, Placebo - Depression, Cognitive Impairment | Phase 4 | Terminated | New York State Psychiatric Institute | 5 | 2021-02-10 | 2023-05-22 |
| DTA (Dopaminergic Therapy for Anhedonia) Study Carbidopa Levodopa, Placebo - Depression, Anhedonia | Phase 4 | Completed | Emory University | 19 | 2021-01-29 | 2024-12-16 |
| Vigor and the LDR in Parkinson Disease carbidopa/levodopa, as prescribed by treating physician - Parkinson Disease | Phase 4 | Completed | University of Michigan | 19 | 2020-02-12 | 2025-07-18 |
| L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults L-DOPA, Placebo Oral Tablet - Major Depressive Disorder, Dysthymia | Phase 4 | Terminated | New York State Psychiatric Institute | 51 | 2019-01-09 | 2023-05-22 |
| A Study of L-DOPA for Depression and Slowing in Older Adults Levodopa - Major Depressive Disorder, Dysthymia | Phase 4 | Completed | New York State Psychiatric Institute | 47 | 2016-08-24 | 2023-06-13 |
| Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753) Placebo, Levodopa - Stress Disorder, Post Traumatic | Phase 4 | Completed | University of Wisconsin, Madison | 103 | 2016-03-01 | 2019-06-25 |
| Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON Levodopa dispersible, Levodopa - Parkinson Disease | Phase 4 | Completed | Seoul National University Hospital | 40 | 2015-06-01 | 2021-05-07 |
| Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) APOKYN, L-dopa, Trimethobenzamide - Parkinson's Disease, Motor Symptoms | Phase 4 | Completed | MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | 127 | 2012-12-01 | 2023-08-14 |
| Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Levodopa/Carbidopa(200mg/50mg), Dopaminergic Agonists - Impulse Control Disorder | Phase 4 | Completed | Sandoz | 150 | 2012-11-01 | 2021-03-10 |
| Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa - Parkinson's Disease | Phase 4 | Terminated | Novartis | 14 | 2008-03-01 | 2011-02-18 |
| Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off Levodopa/carbidopa/entacapone, Levodopa/carbidopa - Parkinson's Disease | Phase 4 | Completed | Novartis | 95 | 2006-10-01 | 2011-03-15 |
| A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease rasagiline mesylate, Rasagiline mesylate plus Mirapex, Rasagiline mesylate with Levodopa - Parkinson's Disease | Phase 4 | Completed | Teva Neuroscience, Inc. | 200 | 2006-10-01 | 2011-04-12 |
| Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit Levodopa (drug), intraduodenal administration - Parkinson Disease | Phase 4 | Completed | University Hospital, Akershus | 10 | 2006-01-01 | 2015-12-30 |
Showing 20 of 28. Sign in to see all of them.
Parkinson Disease (15) · Depression (4) · Anhedonia (2) · Cognitive Dysfunction (2) · Depressive Disorder, Major (2) · Dysthymic Disorder (2) · Alzheimer Disease (1) · Aphasia (1) · Dementia (1) · Disruptive, Impulse Control, and Conduct Disorders (1) · Dyslexia (1) · Retinal Diseases (1) · Stress Disorders, Post-Traumatic (1) · Stroke (1) · Treatment Adherence and Compliance (1)
University Hospital Muenster (5) · Emory University (3) · New York State Psychiatric Institute (3) · Novartis (2) · Ankara Ataturk Sanatorium Training and Research Hospital (1) · Beth Israel Deaconess Medical Center (1) · Bial - Portela C S.A. (1) · MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals (1) · Medical University of Vienna (1) · Orion Corporation, Orion Pharma (1) · Sandoz (1) · Second Affiliated Hospital of Soochow University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Seoul National University Hospital (1) · Technische Universität Dresden (1)
United States (11) · Germany (8) · China (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Austria (1) · Denmark (1) · Finland (1) · Ireland (1) · Italy (1) · Norway (1) · Portugal (1) · Sweden (1) · Turkey (Türkiye) (1)
Caterina Breitenstein, PhD (4) · Stefan Knecht, MD (4) · Bret Rutherford, MD (2) · Jennifer Felger, PhD (2) · Andrew Wighton, BSc (Hons) (1) · Antonie Beiske, PhD, M.D. (1) · Bhadravati SD Sastry, FRCP (1) · Bret R Rutherford, MD (1) · Christofer Lundqvist, PhD, M.D. (1) · Chun-Feng Liu, MD,PhD (1) · Gianpiera H. Ceresoli-Borroni, PhD (1) · Heinz Reichmann, MD (1) · Jee-Young Lee, MD, PhD (1) · Jinwhan Cho, MD (1)
PMID 16880771, PMID 21553090, PMID 22549097, PMID 25588456, PMID 26347184, PMID 27942720, PMID 30361296, PMID 31178096, PMID 31378952, PMID 32919398, PMID 34260994
K23DK144718 (1), P50NS123103 (1), R01MH123660 (1), R21NS114749 (1), R33MH110029 (1), R33MH121625 (1), R61MH121625 (1)